Critical Contrast: Alternate Health (OTCMKTS:AHGIF) versus Pulmonx (NASDAQ:LUNG)

Pulmonx (NASDAQ:LUNG) and Alternate Health (OTCMKTS:AHGIF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Analyst Recommendations

This is a breakdown of current ratings for Pulmonx and Alternate Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	1	4	5	0	2.40
Alternate Health	0	0	0	0	0.00

Pulmonx currently has a consensus target price of $6.81, indicating a potential upside of 256.39%. Given Pulmonx’s stronger consensus rating and higher possible upside, equities analysts plainly believe Pulmonx is more favorable than Alternate Health.

Profitability

This table compares Pulmonx and Alternate Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-61.91%	-77.58%	-37.90%
Alternate Health	N/A	N/A	N/A

Insider & Institutional Ownership

91.0% of Pulmonx shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Pulmonx and Alternate Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$83.79 million	0.94	-$56.39 million	($1.41)	-1.35
Alternate Health	N/A	N/A	N/A	N/A	N/A

Alternate Health has lower revenue, but higher earnings than Pulmonx.

Summary

Pulmonx beats Alternate Health on 6 of the 9 factors compared between the two stocks.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

About Alternate Health

Alternate Health Corp., a diversified healthcare company, provides cloud based software solutions in Canada. It offers medical practice and controlled substance management software, blood analysis and toxicology labs, clinical research, continuing education programs, nutraceutical products, and security and control services to the medical cannabis industry. The company is headquartered in Toronto, Canada.